GPRC5D
G protein-coupled receptor family C group 5 member D
As of the edition of 20 October 2026, GPRC5D (G protein-coupled receptor family C group 5 member D, UniProt Q9NZD1) has 4 drugs tested at it and 3 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9NZD1
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Solved structures
- 3
- Disease areas
- Cancer; Immune system; Blood and lymph; Heart and blood vessels; Nutrition and metabolism; Infections; Nervous system; Skin and connective tissue
- Registered trials of its drugs
- 50
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 3 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Talquetamab | Marketed | Phase 4 | Ends 2035 |
| JNJ-79635322 | Active | Phase 3 | none listed |
| QLS4131 | Active | Phase 2 | none listed |
| SAR446523 | Active | Phase 1 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Engaged | 2 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Johnson & Johnson | Route B |
The other 2 companies at GPRC5D
In the product3 companies in all; 2 are not named here, and no score is.
See the 3 companies at GPRC5D, ranked, with the facts behind eachRequest access. Nothing is shown until you do.